http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007059966-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73f9df14c7d60838e4e41d0c7aef6637 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2006-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51b8cb405faafeddeb7c38387888be54 |
| publicationDate | 2007-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2007059966-A1 |
| titleOfInvention | Detection and treatment of drug associated angioedema |
| abstract | The present invention relates to an in vitro method of diagnosing a drug-associated angioedema or a predisposition thereto in a subject being suspected of having developed or of having a predisposition to develop a drug-associated angioedema or in a subject being suspected of being a carrier for a drug-associated angioedema or in a subject being intended to be treated with a drug associated with the development of angioedema, the method comprising determining in a biological sample from said subject the presence or absence of a disease-associated mutation in a nucleic acid molecule regulating the expression of or encoding coagulation factor XII; wherein the presence of such a mutation is indicative of a drug- associated angioedema or a predisposition thereto. The present invention also relates to a method of diagnosing a drug-associated angioedema or a predisposition thereto in a subject being suspected of having developed or of having a predisposition to develop a drug-associated angioedema or in a subject being suspected of being a carrier for a drug-associated angioedema or in a subject being intended to be treated with a drug associated with the development of angioedema, the method comprising assessing the presence, amount and/or activity of coagulation factor XII in said subject and including the steps of: (a) determining from a biological sample of said subject in vitro, the presence, amount and/or activity of: (i) a (poly)peptide encoded by the coagulation factor XII gene; (ii) a substrate of the (poly)peptide of (i); or (iii) a (poly)peptide processed by the substrate mentioned in (ii); (b) comparing said presence, amount and/or activity with that determined from a reference sample; and (c) diagnosing, based on the difference between the samples compared in step (b), the pathological condition of a drug-associated angioedema or a predisposition thereto. The present invention also relates to a method of identifying a compound modulating coagulation factor XII activity which is suitable as a medicament or a lead compound for a medicament for the treatment and/or prevention of drug-associated angioedema, the method comprising the steps of: (a) in vitro contacting a coagulation factor XII (poly)peptide or a functionally related (poly)peptide with the potential modulator; and (b) testing for modulation of coagulation factor XII activity, wherein modulation of coagulation factor XII activity is indicative of a compound's suitability as a medicament or a lead compound for a medicament for the treatment and/or prevention of drug-associated angioedema. Furthermore, the present invention relates to gene therapy methods and to a kit for diagnosing drug-associated angioedema. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021000102-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10858658-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108064313-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10934544-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108064313-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10883107-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10308941-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018509913-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014019644-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3271482-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I727948-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2008315938-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2664920-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009053050-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016179342-A3 |
| priorityDate | 2005-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1404.